Key result
In patients with NSTEMI or unstable angina, a glucose-insulin-potassium regimen was associated with a 30-day mortality of in the control group.
Why the study?
Does a glucose-insulin-potassium (GIK) regimen reduce 30-day mortality in patients with NSTEMI/unstable angina?
Cohort (n=93)
No
Does a glucose-insulin-potassium (GIK) regimen reduce 30-day mortality in patients with NSTEMI/unstable angina?
In a small prospective cohort of patients with NSTEMI/unstable angina, a GIK regimen was associated with numerically lower 30-day mortality, though the confidence interval was wide.
Answers are grounded in this paper and cite their sources.
GIK should not yet change NSTEMI/unstable angina management; leaves open a possible mortality benefit pending randomized confirmation.
This study was conducted on patients who presented to the cardiology department and were admitted either in cardiology ward or coronary care unit of Sir Sunder Lal Hospital, BHU, Varanasi with a diagnosis of acute coronary syndrome (ACS). Ninety three patients were enrolled in the study. The study period extended from January 2006 to March 2007. Study was a hospital based prospective study that involved estimation of the clinical, echocardiographic features and survival status of patients who presented with ACS, with or without GIK regimen. Based on clinical grounds and electrocardiographic findings patients were enrolled: NSTEMI/unstable angina. The 30 days mortality was 4 of 47 (8.5%) patients receiving GIK compared with 8 of 46 (17%) patients in control group (relative risk [RR], 0.45, 95%; confidence interval [CI] 0.12-1.62). In 85 patients (94.4) without signs of heart failure (Killip class I) 30 days mortalitywas 2 of 42 patients (4.7%) in GIK group vs. 5 of 43 patients (11.67%) in control group (RR 0.38, 95%; CI 0.06-2.07). In 8 (5.6%) patients with signs of HF (Killip class ≥ II), 30 days mortality was 2 of 5 patients (40%) in GIK group vs. 3 of 3 (100%) in control group. In patients with non-ST elevation myocardial infarction (NSTEMI)/ unstable angina, 30 days mortality was significantly lower in GIK group as compared to control group and in patients without signs of heart failure (Killip class I) 30 days mortality was significantly lower as compared to patients with signs of heart failure (Killip class ≥ II).
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2011) conducted a cohort in NSTEMI/unstable angina (n=93). Glucose-insulin-potassium (GIK) regimen vs. Control group (without GIK regimen) was evaluated on 30 days mortality (RR 0.45, 95% CI 0.12-1.62). In patients with NSTEMI or unstable angina, a glucose-insulin-potassium regimen was associated with a 30-day mortality of in the control group.
Synapse has enriched 10 related papers. Consider them for comparative context: